Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombocytopenic, Idiopathic | 9 | 2024 | 49 | 3.550 |
Why?
|
| Anemia, Megaloblastic | 2 | 2019 | 4 | 1.280 |
Why?
|
| Thrombocytopenia | 5 | 2022 | 228 | 1.260 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 3 | 2021 | 28 | 1.030 |
Why?
|
| Autoimmune Diseases | 3 | 2023 | 250 | 0.940 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 195 | 0.860 |
Why?
|
| Eosinophilia | 2 | 2022 | 101 | 0.830 |
Why?
|
| Thiamine Deficiency | 1 | 2019 | 4 | 0.650 |
Why?
|
| Hydroxocobalamin | 1 | 2018 | 9 | 0.620 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 352 | 0.610 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 52 | 0.580 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 141 | 0.570 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1638 | 0.570 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 174 | 0.550 |
Why?
|
| Osteosarcoma | 1 | 2019 | 257 | 0.530 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 430 | 0.470 |
Why?
|
| Thrombosis | 1 | 2019 | 520 | 0.460 |
Why?
|
| Child, Preschool | 14 | 2024 | 13884 | 0.440 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 805 | 0.430 |
Why?
|
| Child | 21 | 2024 | 24231 | 0.400 |
Why?
|
| Disease Progression | 1 | 2018 | 2024 | 0.400 |
Why?
|
| Infant | 10 | 2024 | 12357 | 0.380 |
Why?
|
| Adolescent | 14 | 2024 | 19104 | 0.380 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 849 | 0.360 |
Why?
|
| Prognosis | 5 | 2024 | 4513 | 0.280 |
Why?
|
| Humans | 28 | 2024 | 123092 | 0.260 |
Why?
|
| Male | 16 | 2024 | 60091 | 0.240 |
Why?
|
| Chronic Disease | 3 | 2024 | 1162 | 0.240 |
Why?
|
| Immunoglobulins | 1 | 2024 | 169 | 0.230 |
Why?
|
| Female | 15 | 2024 | 65538 | 0.210 |
Why?
|
| Leukopenia | 1 | 2023 | 44 | 0.210 |
Why?
|
| Primary Myelofibrosis | 1 | 2023 | 50 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 34 | 0.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 54 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 232 | 0.180 |
Why?
|
| Neutropenia | 2 | 2019 | 202 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 175 | 0.180 |
Why?
|
| HIV Infections | 2 | 2022 | 1856 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2022 | 182 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 171 | 0.170 |
Why?
|
| Malnutrition | 1 | 2022 | 196 | 0.170 |
Why?
|
| Orchiectomy | 1 | 2019 | 44 | 0.160 |
Why?
|
| Coombs Test | 1 | 2019 | 6 | 0.160 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2019 | 8 | 0.160 |
Why?
|
| Fatigue | 1 | 2020 | 216 | 0.160 |
Why?
|
| Genotype | 1 | 2024 | 2535 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 88 | 0.150 |
Why?
|
| Hematologic Tests | 1 | 2018 | 34 | 0.150 |
Why?
|
| Radiotherapy | 1 | 2019 | 135 | 0.150 |
Why?
|
| Anemia | 1 | 2022 | 340 | 0.150 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2018 | 39 | 0.150 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 100 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 132 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 141 | 0.150 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 77 | 0.150 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 192 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2024 | 1477 | 0.150 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 102 | 0.150 |
Why?
|
| Failure to Thrive | 1 | 2018 | 90 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 177 | 0.150 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 1 | 2017 | 6 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 151 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2018 | 178 | 0.140 |
Why?
|
| Histiocytes | 1 | 2017 | 23 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2019 | 381 | 0.140 |
Why?
|
| Health Care Costs | 2 | 2018 | 365 | 0.140 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2017 | 31 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 111 | 0.140 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 67 | 0.140 |
Why?
|
| Heart Atria | 1 | 2019 | 313 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 653 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 317 | 0.140 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 78 | 0.130 |
Why?
|
| Rituximab | 1 | 2017 | 155 | 0.130 |
Why?
|
| Adult | 8 | 2023 | 29018 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2018 | 302 | 0.130 |
Why?
|
| Hydroxyurea | 1 | 2016 | 81 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 500 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2582 | 0.130 |
Why?
|
| Bacteremia | 1 | 2019 | 404 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1237 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 420 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2018 | 377 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2017 | 376 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 162 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2022 | 16037 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 3077 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 293 | 0.110 |
Why?
|
| Disease Management | 3 | 2024 | 513 | 0.110 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 221 | 0.110 |
Why?
|
| Neoplasms | 2 | 2018 | 2758 | 0.110 |
Why?
|
| Lamivudine | 2 | 2022 | 25 | 0.100 |
Why?
|
| Age Factors | 1 | 2018 | 2803 | 0.100 |
Why?
|
| Platelet Count | 2 | 2022 | 133 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1256 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2846 | 0.090 |
Why?
|
| Physicians, Family | 1 | 2009 | 38 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2022 | 3240 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2018 | 3316 | 0.080 |
Why?
|
| Papillomavirus Vaccines | 1 | 2009 | 93 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2022 | 12119 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 239 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 284 | 0.060 |
Why?
|
| Mutation | 1 | 2019 | 5772 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 641 | 0.060 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2024 | 229 | 0.050 |
Why?
|
| Risk Factors | 3 | 2022 | 10013 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2022 | 246 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 230 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 235 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 121 | 0.050 |
Why?
|
| Prednisolone | 1 | 2021 | 72 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2021 | 90 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2022 | 333 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 606 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 224 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 304 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 13 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 377 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2017 | 29 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2017 | 85 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 299 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 179 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1309 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 238 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 859 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2404 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 497 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1389 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 1997 | 0.020 |
Why?
|
| Parents | 1 | 2018 | 1031 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3042 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 4227 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5047 | 0.020 |
Why?
|
| Arkansas | 1 | 2009 | 58 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2009 | 284 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3562 | 0.020 |
Why?
|
| Middle Aged | 2 | 2018 | 25993 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8111 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2392 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6027 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 4490 | 0.020 |
Why?
|
| United States | 1 | 2016 | 10645 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 3665 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 19092 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 8839 | 0.010 |
Why?
|